SCHEMBL23758490

SCHEMBL23758490

CCN(CC)c1ccc2cc(C(=O)NCCCOCCC(=O)O)c(=O)oc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
HPGD P15428 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
KDM4E B2RXH2 3/20 0.60
HSD17B10 Q99714 2/20 0.60
SLC16A3 O15427 1/20 0.60
ALOX15 P16050 1/20 0.60
SLC16A1 P53985 1/20 0.60
MEN1 O00255 4/20 0.57
MAPT P10636 4/20 0.57
KMT2A Q03164 4/20 0.57
ATM Q13315 3/20 0.57
MAOB P27338 3/20 0.57
USP2 O75604 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57
GBA1 P04062 1/20 0.55
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.55
CASP1 P29466 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13248272 0.94 ALDH1A1 (0.62) ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10
SCHEMBL13056414 0.91 ALDH1A1 (0.59) ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10
SCHEMBL16202224 0.91 ALDH1A1 (0.58) ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10
SCHEMBL13524273 0.85 ALDH1A1 (0.63) ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10
SCHEMBL13248271 0.84 KMT2A (0.61) ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10
SCHEMBL15298984 0.84 MAOB (0.63) ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10
SCHEMBL984771 0.84 ALDH1A1 (0.59) ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10
SCHEMBL13248267 0.84 ALDH1A1 (0.58) ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10
SCHEMBL17612195 0.84 ALDH1A1 (0.56) ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10
SCHEMBL13056424 0.83 ALDH1A1 (0.55) ALDH1A1HPGDSMN1; SMN2KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11092594-B2 Haptens, hapten conjugates, compositions thereof and method for their preparation and use VENTANA MEDICAL SYSTEMS, INC. (US) 2021-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11092594-B2 Haptens, hapten conjugates, compositions thereof and method for their preparation and use CRBN, AHR, RORB ALDH1A1 2734/4885HPGD 1803/4885SMN1; SMN2 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.